TEE
FOLD

Tibra Equities Europe’s Amicus Therapeutics FOLD Stock Holding History

Tibra Equities Europe’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,800
Closed -$249K – 50
2020
Q4 		$249K Buy
+10,800
New +$221K 0.03% 138
2019
Q2 		– Sell
-43,500
Closed -$592K – 316
2019
Q1 		$592K Buy
+43,500
New +$531K 0.06% 248
2018
Q4 		– Sell
-18,801
Closed -$227K – 222
2018
Q3 		$227K Buy
+18,801
New +$263K 0.03% 191

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tibra Equities Europe's FOLD Position: Q1 2021 in Review

Tibra Equities Europe sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 10,800 shares — an estimated $249K sold.

Tibra Equities Europe first reported a position in FOLD in Q3 2018 and held it in 3 quarters. The position peaked at $592K in Q1 2019. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Tibra Equities Europe reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 10,800 Amicus Therapeutics shares in Q1 2021, an estimated $249K.
  • Tibra Equities Europe first reported a position in Amicus Therapeutics in Q3 2018 and held it in 3 quarters.
  • Tibra Equities Europe's Amicus Therapeutics position peaked at $592K in Q1 2019.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Tibra Equities Europe's 13F filing for Q1 2021, filed 17 May 2021.